Stay updated with breaking news from Nasdaq Ards. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS – Get Rating) was the target of a significant decline in short interest in March. As of March 31st, there was short interest totalling 571,400 shares, a decline of 81.3% from the March 15th total of 3,060,000 shares. Based on an average trading volume of 1,580,000 shares, the days-to-cover ratio is […]
LOS GATOS, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (“Aridis” or the “Company”), a biopharmaceutical...
Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS – Get Rating) was the target of a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 3,060,000 shares, an increase of 323.8% from the February 28th total of 722,100 shares. Based on an average daily volume of 1,530,000 shares, the […]
Wall Street brokerages expect that Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS – Get Rating) will report earnings per share of ($0.48) for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Aridis Pharmaceuticals’ earnings, with estimates ranging from ($0.49) to ($0.46). Aridis Pharmaceuticals reported earnings per share of ($0.55) in the same quarter last […]
Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS – Get Rating) was the target of a large decrease in short interest in April. As of April 15th, there was short interest totalling 72,000 shares, a decrease of 36.3% from the March 31st total of 113,000 shares. Based on an average daily volume of 1,380,000 shares, the days-to-cover ratio is […]